Stem Cell Mobilization - CBMTG

More documents

Recommendations

Info

MUSC - Historical Linear Correlation Between Peripheral Blood CD34+ and Apheresis Product CD34+ Assumption that Plerixafor will lead to a 3 fold increment in CD34+ count in the apheresis product Costa LJ, et al. Bone Marrow Transplant. 2011 Jan;46(1):64-9. 14
Projected number of daily apheresis sessions Projected number of daily apheresis sessions 10 9 8 target 3 x 10e6/Kg target 6 x 10e6/Kg target 9 x 10e6/Kg 7 N G 6 5 G-CSF approach Cost= (3+N G )x F + N G xA 4 3 2 1 0 0 10 20 30 40 50 60 10 peripheral blood CD34+ cells target 3 x 10e6/Kg 9 target 6 x 10e6/Kg 8 target 9 x 10e6/Kg Proceed with the approach with the lowest estimated cost 7 N G+P 6 5 4 G-CSF + Plerixafor approach Cost= (4+N G+P )x F + N G+P xA + N G+P xP 3 2 1 0 0 10 20 30 40 50 60 peripheral blood CD34+ cells N = number of days of collection. F = cost of filgrastim. A = cost of apheresis. P = cost of plerixafor. Costa LJ, et al. Bone Marrow Transplant. 2010. 2011 Jan;46(1):64-9.
Page 1 and 2: Stem Cell Mobilization: Patient Spe
Page 3 and 4: SDF-1 CXCR4 Interaction
Page 5 and 6: Plerixafor • US FDA approval Dec.
Page 7 and 8: QUESTIONS • Can plerixafor use be
Page 9 and 10: Strategy 2 : Plerixafor for patient
Page 11 and 12: Decision based on actual mobilizati
Page 13: Cost-Effective Use of Plerixafor fo
Page 17 and 18: MUSC Algorithm Yes- end of collecti
Page 19 and 20: Algorithm Effectively Guides Plerix
Page 21 and 22: Comparison Between MUSC Algorithm (
Page 23 and 24: MUSC Algorithm (MA) vs CY Mobilizat
Page 25 and 26: Median time from mobilization to tr
Page 27 and 28: Summary • The MUSC Algorithm (MA)
Page 29 and 30: Hematopoietic Graft Composition Acc
Page 31 and 32: Future Questions • Is peg-filgras
Page 33: Stem Cell Mobilization: Patient Spe

Stem Cell Mobilization - CBMTG

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?